Live Breaking News & Updates on Triple Hormone Receptor Agonist

1. In this randomized controlled trial, the triple-hormone-receptor agonist retatrutide was superior to placebo in reducing body weight among patients with obesity. 2. The most common adverse events were gastrointestinal symptoms and increased heart rate. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity is an increasingly prevalent chronic disease that can be difficult to effectively ....

Minute Medicine Inc , Rating Level , Cardiovascular Disease , Chronic Disease , Glp 1 Agonist , Glucagon Receptor , Glucagon Like Peptide 1 Receptor Agonists , Glucose Dependent Insulinotropic Polypeptide , Metabolic Syndrome , Triple Hormone Receptor Agonist ,